10-Q: Cocrystal Pharma Q1 2026: Net Loss Widens Amidst R&D Focus

Cocrystal Pharma reported a net loss of $2.3 million for Q1 2026, with cash reserves projected to last less than 12 months, while advancing its antiviral drug candidates.

Summary

• Cocrystal Pharma reported a net loss of $2.3 million for the first quarter ended March 31, 2026, a slight decrease from $2.3 million in the same period of 2025.
• The company's cash and restricted cash balance stood at $4.76 million as of March 31, 2026, with management indicating that current resources are insufficient to fund operations beyond the next 12 months.
• Research and development expenses remained high at $1.37 million, while general and administrative expenses increased to $1.21 million.
• Grant income of $225,000 was recognized in the quarter, primarily related to an NIH/NIAID award for influenza A and B antiviral development.
• The company is advancing its norovirus and coronavirus candidate, CDI-988, with a Phase 1b challenge study underway in the U.S. and has received FDA Fast Track designation.
• Development of influenza candidate CC-42344 is contingent on resolving a dispute with a UK CRO and securing additional capital for further studies.
• The company continues to explore opportunities for its Hepatitis C candidate, CC-31244, seeking a partner for further clinical development.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant going concern warning, ongoing legal disputes, and the company's reliance on future capital raises, despite positive developments like the FDA Fast Track designation.

Positives

• Received FDA Fast Track designation for CDI-988, potentially accelerating its development and review process.
• Commenced Phase 1b challenge study for CDI-988 in the U.S. to evaluate its preventative and treatment potential for norovirus infections.
• Recognized $225,000 in grant income from an NIH/NIAID award supporting influenza A and B antiviral development.
• Favorable safety and tolerability data from Phase 1 studies of CDI-988 have been reported.
• CC-42344 showed potential efficacy against the new Texas avian flu strain in in vitro studies.
• The company has a clear focus on developing novel antiviral drug candidates for significant unmet medical needs.

Negatives

• Reported a net loss of $2.3 million for the quarter, continuing a trend of operating losses.
• Management estimates current resources will not be sufficient to fund operations beyond the next 12 months, raising going concern doubts.
• The Influenza A program faces significant risks and uncertainties following an initial Phase 2a study that failed to yield scientifically viable results.
• A dispute has arisen with a UK clinical research organization (CRO) regarding the Phase 2a study for CC-42344, with the company seeking a refund of $6.3 million or a redo of the study.
• General and administrative expenses increased by $229,000, largely due to higher legal and consultant costs.
• The company has not generated sustained positive cash flow and has incurred net losses since inception.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern due to recurring net losses and negative operating cash flows, and the insufficiency of current resources to fund operations beyond the next 12 months.
• The Influenza A program faces significant risks and uncertainties following an initial Phase 2a study that failed to yield scientifically viable results, with a dispute ongoing with the CRO.
• The Company may have to delay, reduce the scope of, or eliminate one or more of its clinical trials or research and development programs if it is unable to obtain adequate capital.
• The Company could be forced to cease operations or substantially curtail its drug development activities if it is unable to obtain adequate capital.
• Future cash requirements depend on numerous factors including economic conditions, product approval and success, clinical trial outcomes, patent costs, competitive products, financing availability, market development, and legal proceedings.
• Products developed by the Company require clearance from regulatory agencies like the FDA, and denial or delay of clearance could materially and adversely impact the business.
• Inflationary pressures, particularly due to U.S. tariff policy, could increase operating costs and stress working capital resources.
• The Company is subject to foreign currency exchange rate fluctuations due to its Australian subsidiary.

Future Outlook

The Company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases. Management believes current resources are insufficient to fund operations beyond the next 12 months, necessitating the continued need for additional capital through equity offerings or strategic partnerships. The success of future operations is dependent on obtaining regulatory approvals, successful product commercialization, and securing adequate financing.

Management Comments

• "We believe that our current resources will not be sufficient to fund our operations beyond the next 12 months."
• "The Company will need to continue obtaining adequate capital to fund operating losses until it becomes profitable."
• "We have identified promising preclinical and clinical-stage antiviral compounds for unmet medical needs caused by RNA viruses including norovirus, influenza virus, coronaviruses (including SARS-CoV-2 and MERS-COV), respiratory virus infections and hepatitis C virus (HCV)."
• "We believe CDI-988 represents the only oral pan-viral antiviral in development for the treatment and prevention of viral gastroenteritis caused by noroviruses, and coronaviruses, including SARS-CoV-2 and its variants."
• "Subject to resolution of this issue or our raising capital to conduct another study, we plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A."

Industry Context

StockSavvy.ai notes that Cocrystal Pharma operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on antiviral drug development. The company's progress with CDI-988, particularly its Fast Track designation for norovirus, aligns with the industry's ongoing efforts to address significant viral threats. However, the challenges faced with the influenza program and the ongoing need for significant funding highlight the inherent risks and long development timelines typical in this industry.

Comparison to Industry Standards

• The net loss of $2.3 million for the quarter is consistent with early-stage biopharmaceutical companies that are heavily invested in research and development without significant revenue streams.
• The cash burn rate of approximately $2.34 million per quarter is within the typical range for companies at this stage, but the projection of less than 12 months of runway is a critical concern, often prompting capital raises or strategic partnerships.
• The pursuit of oral antiviral treatments for diseases like influenza and norovirus aligns with industry trends seeking more convenient and effective therapeutic options.
• The FDA Fast Track designation for CDI-988 is a positive indicator, as it suggests the drug candidate addresses a serious condition with an unmet medical need, a common pathway for promising therapies in development.
• The dispute with the CRO over the CC-42344 Phase 2a study highlights the operational and financial risks associated with outsourcing clinical trials, a common practice in the industry.

Legal Proceedings

• A dispute has arisen with the United Kingdom clinical research organization (CRO) that performed the Phase 2a study for CC-42344. The Company contends the CRO breached its agreement and is seeking a refund of $6,309,000 or a redo of the study. The CRO denies liability and seeks an additional $600,000. The Company has initiated arbitration to resolve this dispute.

Related Party Transactions

• The lessor of the Miami, Florida lease is a limited liability company controlled by Dr. Phillip Frost, a director and principal stockholder of the Company. Operating lease expense to this related party was $16,000 for the three months ended March 31, 2026 and 2025.
• The Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and principal stockholder, on August 14, 2024. Annualized rent expense is approximately $64,000. Lease deposit was $4,000, and total rent and other expenses paid were $16,000 for each of the three months ended March 31, 2026 and 2025.

Stakeholder Impact

• Shareholders face continued dilution risk due to the potential need for future equity financings to sustain operations.
• Employees may face uncertainty regarding job security if the company cannot secure sufficient funding to continue operations.
• Creditors and suppliers may face payment delays if the company's liquidity situation deteriorates further.
• The company's ability to attract and retain qualified personnel could be impacted by the going concern uncertainty and the need for future capital raises.

Next Steps

• Continue enrollment and evaluation of the Phase 1b challenge study for CDI-988 in the U.S.
• Resolve the dispute with the UK CRO regarding the CC-42344 Phase 2a study or secure capital for a new study.
• Continue development of CC-42344 as a treatment for pandemic and seasonal influenza A, subject to dispute resolution and capital availability.
• Continue pursuing partnerships for further clinical development of CC-31244 for Hepatitis C.
• Seek additional capital through private or public equity offerings or strategic partnerships to fund ongoing operations and development.

Key Dates

Recommendation

Cocrystal Pharma's Q1 2026 filing presents a mixed picture. While the company has achieved positive milestones such as FDA Fast Track designation for CDI-988 and progress in its norovirus program, the significant going concern warning, substantial net loss, and ongoing legal dispute over the influenza program are major red flags. The company's survival hinges on its ability to secure substantial additional funding, which carries significant dilution risk for existing shareholders. Given these uncertainties, a 'hold' recommendation is appropriate, advising investors to monitor future financing activities and clinical trial progress closely.

Keywords

Cocrystal Pharma, 10-Q, Quarterly Report, Antiviral, Biopharmaceutical, Clinical Stage, Drug Development, Norovirus, Influenza, Coronavirus, Hepatitis C, CDI-988, CC-42344, FDA Fast Track, Going Concern, Net Loss, R&D Expenses